Top-Rated StocksTop-RatedNASDAQ:ROIV Roivant Sciences (ROIV) Stock Price, News & Analysis $12.05 +0.01 (+0.08%) (As of 09/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Roivant Sciences alerts: Email Address About Roivant Sciences Stock (NASDAQ:ROIV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Roivant Sciences alerts:Sign Up Key Stats Today's Range$11.88▼$12.2450-Day Range$10.17▼$12.5052-Week Range$8.24▼$13.24Volume5.35 million shsAverage Volume5.70 million shsMarket Capitalization$8.90 billionP/E Ratio2.38Dividend YieldN/APrice Target$17.15Consensus RatingModerate Buy Company OverviewRoivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.Read More… Central Bank Abandons USD (Ad)Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold. Click here now to get your free 'Protect Your Wealth' Guide. Roivant Sciences Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 70th PercentileRoivant Sciences scored higher than 70% of companies evaluated by MarketBeat, and ranked 320th out of 995 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingRoivant Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRoivant Sciences has only been the subject of 4 research reports in the past 90 days.Read more about Roivant Sciences' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Roivant Sciences are expected to grow in the coming year, from ($1.14) to ($1.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Roivant Sciences is 2.38, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.27.Price to Earnings Ratio vs. SectorThe P/E ratio of Roivant Sciences is 2.38, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 143.49.Price to Book Value per Share RatioRoivant Sciences has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Roivant Sciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.62% of the float of Roivant Sciences has been sold short.Short Interest Ratio / Days to CoverRoivant Sciences has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Roivant Sciences has recently decreased by 6.55%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRoivant Sciences does not currently pay a dividend.Dividend GrowthRoivant Sciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.62% of the float of Roivant Sciences has been sold short.Short Interest Ratio / Days to CoverRoivant Sciences has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Roivant Sciences has recently decreased by 6.55%, indicating that investor sentiment is improving significantly. News and Social Media2.6 / 5News Sentiment0.62 News SentimentRoivant Sciences has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Roivant Sciences this week, compared to 5 articles on an average week.Search Interest26 people have searched for ROIV on MarketBeat in the last 30 days. This is an increase of 160% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Roivant Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Roivant Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of Roivant Sciences is held by insiders.Percentage Held by Institutions64.76% of the stock of Roivant Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Roivant Sciences' insider trading history. Receive ROIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roivant Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ROIV Stock News HeadlinesBayer Targets Expanded Use Approval For Prostate Cancer Drug, Reveals Encouraging Data From Pivotal StudySeptember 16 at 3:25 PM | benzinga.comVivek Ramaswamy to Host New Roundtable Show for Fox NationSeptember 16 at 3:25 PM | msn.com Is A Starlink IPO Coming In 2024?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.September 17, 2024 | Paradigm Press (Ad)Buy Rating Issued on Roivant Sciences Following Promising Pulmovant Data and Strategic Asset AcquisitionSeptember 16 at 3:25 PM | markets.businessinsider.comRoivant Sciences (NASDAQ:ROIV) Given "Buy" Rating at HC WainwrightSeptember 13, 2024 | americanbankingnews.comL'action Roivant Sciences conserve sa recommandation d'achat, l'analyste voyant un potentiel dans le nouveau traitement de l'HP-PIDSeptember 12, 2024 | fr.investing.comRoivant Sciences (NASDAQ:ROIV) Given New $12.50 Price Target at Bank of AmericaSeptember 12, 2024 | americanbankingnews.comTD Cowen maintient sa recommandation d'achat sur les actions de Roivant Sciences, réitère sa note "Conserver"September 11, 2024 | fr.investing.comSee More Headlines ROIV Stock Analysis - Frequently Asked Questions How have ROIV shares performed this year? Roivant Sciences' stock was trading at $11.23 on January 1st, 2024. Since then, ROIV stock has increased by 7.3% and is now trading at $12.05. View the best growth stocks for 2024 here. How were Roivant Sciences' earnings last quarter? Roivant Sciences Ltd. (NASDAQ:ROIV) released its quarterly earnings results on Thursday, August, 8th. The company reported $0.12 earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.33. The firm's revenue was up 155.1% compared to the same quarter last year. Who are Roivant Sciences' major shareholders? Top institutional shareholders of Roivant Sciences include Rubric Capital Management LP (3.11%), DME Capital Management LP (0.65%), BlackBarn Capital Partners LP (0.42%) and Troluce Capital Advisors LLC (0.40%). Insiders that own company stock include Pharma Technologies Ltd Dexcel, Sciences Ltd Roivant, Svf Investments (Uk) Ltd, Vivek Ramaswamy, Financial Lp Qvt, Keith S Manchester, Matthew Gline, Global Investors Lp Viking, Eric Venker, Richard Pulik and Rakhi Kumar. View institutional ownership trends. How do I buy shares of Roivant Sciences? Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/08/2024Today9/17/2024Next Earnings (Estimated)11/11/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ROIV CUSIPN/A CIK1635088 Webroivant.com Phone44-20-7400-3347FaxN/AEmployees860Year FoundedN/APrice Target and Rating Average Stock Price Target$17.15 High Stock Price Target$23.00 Low Stock Price Target$12.50 Potential Upside/Downside+40.9%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$5.06 Trailing P/E Ratio2.41 Forward P/E RatioN/A P/E GrowthN/ANet Income$4.35 billion Net Margins2,991.75% Pretax Margin2,937.20% Return on Equity-17.23% Return on Assets-15.10% Debt Debt-to-Equity Ratio0.05 Current Ratio27.91 Quick Ratio27.91 Sales & Book Value Annual Sales$158.30 million Price / Sales56.79 Cash FlowN/A Price / Cash FlowN/A Book Value$7.99 per share Price / Book1.52Miscellaneous Outstanding Shares738,722,000Free Float704,741,000Market Cap$8.99 billion OptionableOptionable Beta1.25 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report This page (NASDAQ:ROIV) was last updated on 9/17/2024 by MarketBeat.com Staff From Our PartnersSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredWall Street Insider Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | SponsoredKamala Harris and The Woke Progressive NightmareNew research from Jim Rickards - former advisor to the CIA - reveals shocking predictions about an “Election M...Paradigm Press | SponsoredJeff Bezos Just Humiliated Elon MuskThe Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next...InvestorPlace | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roivant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Roivant Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
